Wuxi PharmaTech Pushing Ahead with $3bn Go-Private Deal

The continuous development of Wuxi PharmaTech needs ongoing financial support, and while US listing has been an important source for funding, the major Chinese provider of contract development services to the global pharma industry is now looking to go private in a move that aims to take advantage of favorable investor sentiment and bring value to shareholders.